70 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 30 June 2022 FINANCIAL REPORT Note 32. Earnings per share Consolidated 2022 2021 $ $ Loss after income tax attributable to the owners of Kazia Therapeutics Limited (24,647,815) (8,421,960) Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 132,467,686 117,674,543 Weighted average number of ordinary shares used in calculating diluted earnings per share 132,467,686 117,674,543 Cents Cents Basic earnings per share (18.61) (7.16) Diluted earnings per share (18.61) (7.16) Note 33. Share-based payments All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $1,674,581 was recognised. Number of options 2022 Weighted average exercise price 2022 Number of options 2021 Weighted average exercise price 2021 Outstanding at the beginning of the financial year 4,219,000 $0.8911 2,775,167 $0.7970 Granted 4,800,000 $1.6110 2,200,000 $1.0915 Exercised (25,000) $0.6700 (441,500) $0.6195 Expired (338,500) $1.1123 (314,667) $1.8473 Outstanding at the end of the financial year 8,655,500 $1.2826 4,219,000 $0.8911 Exercisable at the end of the financial year 3,180,500 $0.8770 2,506,667 $0.6195
RkJQdWJsaXNoZXIy MjE2NDg3